BioStem Technologies, Inc. (BSEM)
| Market Cap | 77.19M |
| Revenue (ttm) | 34.59M -49.1% |
| Net Income | -28.29M |
| EPS | -1.67 |
| Shares Out | 17.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,241 |
| Open | 4.230 |
| Previous Close | 4.175 |
| Day's Range | 4.170 - 4.450 |
| 52-Week Range | 2.251 - 8.400 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About BSEM
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a hu... [Read more]
Financial Performance
Financial StatementsNews
BioStem Technologies reports GPO contract coverage for Vendaje, Vendaje AC
BioStem Technologies (BSEM) announced that Vendaje and Vendaje AC have been added to the company’s existing contracts with Vizient and Premier., two group purchasing organizations. The products are av...
BioStem Technologies Transcript: Micro-Cap Virtual Conference
A strategic shift to a surgical-centric model, expanded board, and Nasdaq uplisting have positioned the company to target a $26 billion market with a diversified, clinically proven product portfolio. Sequential revenue growth, margin recovery plans, and strong clinical evidence support a positive outlook.
BioStem Technologies Slides: Company presentation
BioStem Technologies has posted slides in relation to its latest quarterly earnings report, which was published on August 19, 2026.
BioStem Technologies Earnings Call Transcript: Q2 2026
Revenue grew to $7.9M in Q2 2026, driven by hospital segment expansion and commercial investments. Gross margin held at 61%, with guidance raised to $26–$29M for the year. Uplisting to Nasdaq and new patents support growth, while a $10M milestone payment is pending.
BioStem Technologies Quarterly report: Q2 2026
BioStem Technologies has published its Q2 2026 quarterly earnings report on August 12, 2026.
BioStem Technologies Earnings release: Q2 2026
BioStem Technologies released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
BioStem files registration statement with SEC, to pursue Nasdaq listing
BioStem Technologies (BSEM) announced the filing of a Form 10 registration statement with the SEC to register its shares of common stock pursuant to the Securities Exchange Act of 1934,…
BioStem Technologies issued four U.S. design patents for allograft technology
BioStem Technologies (BSEM) announced that the USPTO has issued four U.S. design patents covering the company’s proprietary fenestrated human placental allograft technologies. The four patents further...
BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies
Company Continues to Expand Intellectual Property Portfolio Supporting Advanced Placental Allograft Innovation POMPANO BEACH, FL / ACCESS Newswire / July 8, 2026 / BioStem Technologies, Inc. (OTCID:BS...
BioStem Technologies announces notice of allowance for four patents
BioStem Technologies (BSEM) announced that the United States Patent and Trademark Office, or USPTO, has issued notices of allowance for four new divisional U.S. design patent applications related to i...
BioStem Technologies price target lowered to $7 from $9 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on BioStem Technologies (BSEM) to $7 from $9 and keeps a Buy rating on the shares. The firm said that the physician-office channel…
Biostem Technologies initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Biostem Technologies (BSEM) with a Buy rating and $9 price target While the decline in industry revenues has resulted in depressed ...
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Le...
BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies
BioTissue Deepens Commitment to Ocular Market Leadership MIAMI, Jan. 21, 2026 /PRNewswire/ -- BioTissue Holdings, Inc, a leader in harnessing the unique properties of human birth tissue to facilitate ...
BioStem Technologies Slides: Conference presentation
BioStem Technologies has posted slides in relation to its latest quarterly earnings report, which was published on January 10, 2026.
BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant
POMPANO BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercializatio...
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-...
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies CEO to Present at Biotech Showcase 2025
POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT
Presentation to be webcast, with management participating in 1-on-1 meetings at the Luxe Sunset Boulevard Hotel in Los Angeles Pompano Beach, Florida--(Newsfile Corp. - October 23, 2024) - BioStem Tec...
BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
POMPANO BEACH, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-der...
BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments
Miami, Florida--(Newsfile Corp. - July 16, 2024) - Innovation is the lifeblood of the MedTech sector. Literally.
UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
Please note: this Update is being issued for ticker indexing purposes. The content of the release itself remains the same.
PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive interview with Jason Matuszewski, CEO of BioStem Technologies, Inc. ( OTC: BSEM). Following a successful start to 20...
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts
POMPANO BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...